Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Supplementary Dataset 11a - SILAC data for HEK293T-Subtiligase-TM Pervanadate treated vs untreated

ABSTRACT: This dataset contains SILAC data for HEK293T-subtiligase-TM cells, pervanadate treated vs. untreated. In Q20180412-02 and Q20180412-04, light cells were pervanadate treated and heavy cells were the control. In Q20180412-06 and Q20180412-08, heavy cells were pervandate treated and light cells were the control.

INSTRUMENT(S): QExactive Plus

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: James A. Wells

PROVIDER: MSV000084992 | MassIVE | Thu Feb 20 21:17:00 GMT 2020

SECONDARY ACCESSION(S): PXD017669

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Supplementary Dataset 11c - SILAC data for HEK293T-Subtiligase-Y217D-TM Pervanadate treated vs untreated

Project description:This dataset contains SILAC data for HEK293T-subtiligase-Y217D-TM cells, pervanadate treated vs. untreated. In Q20180422-04, light cells were pervanadate treated and heavy cells were the control. In Q20180422-08 and Q20180422-10, heavy cells were pervanadate treated and light cells were the control.

2020-02-21 | MSV000084995 | MassIVE

Supplementary Dataset 11b - SILAC data for HEK293T-Subtiligase-Y217K-TM Pervanadate treated vs untreated

Project description:This dataset contains SILAC data for HEK293T-Subtiligase-Y217K-TM cells, pervanadate treated vs untreated. In Q20180417-03 and Q20180417-05, light cells were pervanadate treated and heavy cells were the control. In Q20180417-07 and Q20180417-09, heavy cells were pervanadate treated and light cells were the control.

2020-02-21 | MSV000084994 | MassIVE

E-GEOD-26241

Project description:Expression data from TGFbeta-treated control or aPKC silenced A549 cells

2025-01-24 | E-GEOD-26241 | ExpressionAtlas

Phosphoproteomic Response To MEK Inhibition

Project description:SILAC Heavy and Light cells were treated for 24 hours with each MEKi vs. Control in duplicate (Heavy/Light as well as Light/Heavy). For phosphoproteomic analysis, cells were treated for either 30 minutes or 24 hours with each MEKi vs. Control.

2019-11-12 | PXD002621 | Pride

E-GEOD-33552

Project description:Expression data from MDA-MB-231 cell line treated with Zoledronate, or Fluvastatin, or mock-treated control cells.

2025-01-24 | E-GEOD-33552 | ExpressionAtlas

Quantitative SILAC phosphoproteomics and proteomics of HL60 cells treated with covalent CDK7 inhibitor SY351

Project description:Using the covalent inhibitor SY-351 and quantitative SILAC phosphoproteomics, we identified CDK7 kinase substrates in human cells. We performed a double-label SILAC phosphoproteomics experiment, in which we metabolically labeled HL60 cells with light labeled (Lys0, Arg0) or heavy labeled (Lys8, Arg8) amino acids, which were treated with vehicle (DMSO) or 50 nM SY-351, followed by phosphopeptide enrichment and mass spectrometry analysis. The experimental design included two biological replicates of SY-351 treated heavy cells compared with DMSO treated light cells, a label-flip biological replicate of SY-351 light cells compared with DMSO treated heavy cells, and a null condition for which both heavy and light were treated with DMSO. The label-flip and null conditions control for systematic errors in phosphopeptide Heavy:Light SILAC ratios that are independent of the SY-351 treatment effect. We used a linear statistical model to capture these systematic errors, which improved our statistical power to detect phosphorylation sites that changed in abundance with SY-351 treatment.

2020-06-10 | MSV000085575 | MassIVE

E-MTAB-5577

Project description:RNA-seq of HEK293T cells treated with control b-globin siRNA and Pat1b siRNA

2025-01-23 | E-MTAB-5577 | ExpressionAtlas

SARS-CoV-2 Mpro subtiligase-mediated N-terminomics in Jurkat

Project description:Subtiligase-based N-terminomics study with 0.5 uM SARS-CoV-2 Mpro in Jurkat cell lysates. Independent duplicates were injected with (L20200924-06, L20200924-07) and without FAIMS (L20200927-01-001, L20200927-02-002).

2021-12-17 | MSV000088584 | MassIVE

E-GEOD-71421

Project description:RNA-seq of coding RNA in primary human hematopoietic cells treated with UNC0638 or DMSO control

2025-01-24 | E-GEOD-71421 | ExpressionAtlas

E-GEOD-19777

Project description:Antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells

2025-01-24 | E-GEOD-19777 | ExpressionAtlas